Company profile
Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07037862 | phase1_2 | recruiting | 2025-06-30 | 2029-03-28 | Entrada Therapeutics, Inc. | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 |
| NCT07038824 | phase1_2 | recruiting | 2025-08-30 | 2029-03-01 | Entrada Therapeutics, Inc. | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 |
| NCT07682129 | phase2 | not_yet_recruiting | 2026-08-01 | 2032-03-01 | Entrada Therapeutics, Inc. | Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) |
FDA applications (0)
No records yet.